Canine Congestive Heart Failure: Staging and Therapeutic Plan

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Canine congestive heart failure (CHF) is staged using the ACVIM system (A: at-risk, B1/B2: structural disease without/with cardiomegaly, C: clinical signs, D: refractory). Stage B2 is the threshold for initiating therapy.
• The therapeutic backbone for canine CHF involves neurohormonal modulation (ACE inhibitors from Stage B2), hemodynamic support (pimobendan mandatory at Stage C), and congestion control (loop diuretics like furosemide).
• Pimobendan, an inodilator, is first-line inotropic support for Stage C/D CHF and may be considered for selected Stage B2 dogs with significant cardiomegaly to delay CHF onset.
• Loop diuretics (furosemide) are crucial for relieving pulmonary edema and effusions, with the goal of using the lowest effective dose to maintain the dog free of congestion ("dry weight") and minimize RAAS activation and prerenal azotemia.
• Monitoring involves regular assessment of body weight, resting respiratory rate, renal parameters (creatinine, BUN), and electrolytes, with rechecks scheduled 7-14 days after dose changes and every 1-3 months when stable.
• Stage D refractory CHF necessitates diuretic intensification (e.g., adding thiazides or using torsemide) and adjunctive therapies, with careful consideration of arrhythmias and owner discussion regarding prognosis and quality of life.

This article provides a stage-based therapeutic framework for canine congestive heart failure (CHF), intended for practicing veterinarians constructing long-term management plans. It covers the ACVIM staging system, drug selection by stage, monitoring protocols, and common therapeutic failure modes. Emergency stabilization of acute pulmonary edema or cardiogenic shock is excluded. The reader is assumed to be comfortable with cardiac auscultation, thoracic radiography, and basic echocardiography.

The therapeutic plan for canine CHF rests on a foundation of neurohormonal modulation, hemodynamic support, and congestion control. Chronic activation of the renin-angiotensin-aldosterone system (RAAS) promotes and perpetuates the syndrome through pro-fibrotic, pro-inflammatory, and pro-hypertrophic remodeling of cardiovascular and renal tissues, as detailed in the review of RAAS suppression in cardiovascular and renal disease. Suppressing this cascade is therefore central to slowing disease progression, also to relieving clinical signs.

At a Glance

Pathophysiology Relevant to Therapy

Heart failure progresses through compensatory mechanisms that initially maintain cardiac output but ultimately become maladaptive. The RAAS is activated early, increasing circulating and tissue angiotensin II and aldosterone. These mediators drive myocardial hypertrophy, interstitial fibrosis, and sodium retention. The same review of RAAS suppression emphasizes that this remodeling occurs in both cardiac and renal tissues, which explains why renal function must be monitored alongside cardiac status during treatment.

Proinflammatory cytokine signaling also contributes to the failing phenotype. Tumor necrosis factor is not expressed by the normal heart, but the failing heart produces it in substantial quantities, and the level of expression correlates with disease severity, as described in the review of TNF in heart failure pathophysiology. This cytokine axis is not currently a direct therapeutic target in canine CHF, but it explains the systemic signs of cachexia and malaise seen in advanced disease.

Tachycardia-induced cardiomyopathy deserves specific mention because it is a reversible cause of systolic dysfunction. Sustained rapid pacing in experimental models produces severe biventricular systolic dysfunction within weeks, yet hemodynamic variables approach control levels within 48 hours of rate control, as summarized in the review of tachycardia-induced cardiomyopathy. In clinical practice, this means that any dog presenting with CHF and a sustained tachyarrhythmia, particularly atrial fibrillation with a rapid ventricular response, should have rate control prioritized as a therapeutic intervention in its own right, also as symptomatic treatment.

The ACVIM Staging System

The staging framework used throughout this article is the consensus classification published by the ACVIM consensus statements. It is a four-stage system that describes disease progression, not acute severity.

Stage A comprises dogs at high risk for heart disease but without identifiable structural abnormalities. Breeds predisposed to myxomatous mitral valve disease or dilated cardiomyopathy fall into this category. No therapy is indicated at Stage A, but periodic screening examinations are appropriate.

Stage B includes dogs with structural heart disease that have never shown clinical signs of CHF. Stage B is subdivided into B1, where auscultatory or echocardiographic abnormalities exist without radiographic or echocardiographic cardiomegaly, and B2, where cardiomegaly is present. The B2 designation is the threshold at which intervention is recommended in many consensus guidelines, because this is the point at which the risk of progression to clinical CHF becomes substantial enough to justify daily medication.

Stage C denotes dogs with current or past clinical signs of CHF, such as cough, tachypnea, respiratory distress, or exercise intolerance attributable to heart failure. Stage D describes dogs that are refractory to standard Stage C therapy and require additional or alternative interventions.

Neurohormonal Modulation as the Therapeutic Backbone

The rationale for RAAS suppression is straightforward: chronic angiotensin II and aldosterone excess is directly harmful to the myocardium and kidneys. The review of RAAS suppression notes that despite the availability of multiple RAAS-suppressing agents, morbidity from heart failure remains high, which argues for early and consistent use instead of reserving these drugs for advanced disease.

Angiotensin-converting enzyme inhibitors reduce angiotensin II formation and aldosterone secretion. They also reduce afterload through vasodilation and decrease sodium retention. Their benefits in canine CHF are well established, and they are considered first-line therapy from Stage B2 onward.

Aldosterone breakthrough is a recognized phenomenon in which aldosterone levels rise despite ACE inhibition. This has driven interest in aldosterone receptor antagonists as adjunctive therapy, particularly in dogs that remain congested or that develop refractory effusions despite standard therapy.

Inotropic Support and the Role of Pimobendan

Pimobendan is a positive inotrope with vasodilatory properties, classified as an inodilator. Its mechanism combines phosphodiesterase III inhibition with calcium sensitization of the cardiac myofilaments. It is the only positive inotrope that has consistently demonstrated survival benefit in canine CHF and is considered first-line therapy for Stage C and D disease.

The timing of pimobendan initiation is a point of active clinical debate. Some consensus recommendations support its use in Stage B2 for dogs with significant cardiomegaly, particularly those with mitral valve disease, based on evidence that it delays the onset of CHF. Other clinicians prefer to reserve it until Stage C. The decision should be made on a case-by-case basis, weighing the dog's echocardiographic parameters, rate of progression, and owner capacity for twice-daily dosing.

Diuretic Therapy and Congestion Control

Loop diuretics are the most effective agents for relieving pulmonary edema and effusions. Furosemide is the standard choice. The guiding principle is to use the lowest dose that maintains the dog free of congestion, because diuretic-induced activation of the RAAS can accelerate remodeling and because over-diuresis causes prerenal azotemia and weakness.

Diuretic dosing must be individualized. A dog presenting with severe pulmonary edema requires aggressive initial diuresis, but once stable, the dose should be tapered to the minimum effective maintenance level. Body weight should be monitored at every recheck, because a gain of several percent over baseline often precedes overt congestive signs.

Monitoring and Therapeutic Adjustment

The monitoring plan for a dog on CHF therapy has three objectives: confirm congestion control, detect drug adverse effects, and identify disease progression. Thoracic radiographs remain the most practical tool for assessing pulmonary edema. Body weight, respiratory rate at rest, and appetite are useful clinical indicators that owners can track at home.

Serum biochemistry should be evaluated within 7 to 14 days of starting or changing an ACE inhibitor or diuretic, with particular attention to creatinine, urea, and potassium. Renal function often declines modestly when RAAS suppression and diuresis are initiated together, and a stable mild azotemia is acceptable if the dog is eating well and free of congestion. A progressive rise in creatinine, however, warrants dose reduction of the diuretic, the ACE inhibitor, or both.

Echocardiography is indicated when clinical signs progress despite apparently adequate medical therapy, because it may reveal a new structural lesion, worsening systolic function, or the development of pulmonary hypertension. It is also the definitive tool for confirming the diagnosis of tachycardia-induced cardiomyopathy when an arrhythmia is present, and for documenting recovery after rate control is achieved.

Stage C Therapy: The Congested Patient

Stage C is defined by current or historical clinical signs of heart failure, including pulmonary edema, pleural effusion, ascites, or exercise intolerance attributable to structural heart disease. Therapy at this stage is directed at three objectives: relief of congestion, neurohormonal suppression, and hemodynamic support. The combination of pimobendan, a loop diuretic, and an angiotensin-converting enzyme (ACE) inhibitor constitutes the standard triple therapy for most dogs with Stage C heart failure. This combination addresses the maladaptive neurohormonal cascade that characterizes the syndrome, as chronic activation of the renin-angiotensin-aldosterone system promotes fibrosis, hypertrophy, and progressive dysfunction in cardiovascular tissues The renin-angiotensin-aldosterone system and its suppression.

Initiation Sequence and Drug Selection

When a dog presents with active congestion, the sequence of drug initiation matters. Furosemide is administered first, by injection in the hospital setting, to rapidly reduce preload and relieve respiratory distress. Once the dog is stable and eating, oral furosemide is initiated and titrated to the lowest effective dose. Pimobendan is started early, typically within the first 24 hours of hospitalization, because its positive inotropic and vasodilatory effects improve forward output and support renal perfusion. An ACE inhibitor is introduced once the dog is hemodynamically stable and renal function has been assessed, usually within 48 to 72 hours of presentation.

The choice of ACE inhibitor is less important than consistent administration. Enalapril and benazepril are the most commonly used agents in canine practice. Benazepril offers the theoretical advantage of biliary excretion in dogs with reduced glomerular filtration, but both drugs require monitoring of renal parameters after initiation. Spironolactone is added in dogs with persistent or recurrent effusions despite adequate doses of furosemide and an ACE inhibitor, particularly when right-sided signs predominate. Aldosterone breakthrough, where circulating aldosterone levels rise despite ACE inhibition, provides the rationale for this addition The renin-angiotensin-aldosterone system and its suppression.

Furosemide Titration and the Dry Weight Concept

Furosemide dosing is dynamic, not static. The goal is to achieve the lowest dose that maintains the dog free of congestion, a concept referred to as the dry weight. Body weight is measured daily during the initial stabilization period and at each recheck thereafter. A weight gain of 2% to 3% over the established dry weight often precedes audible crackles or visible effusion and should prompt a temporary furosemide dose increase.

The table below outlines the monitoring parameters that guide furosemide adjustment.

Resting respiratory rate is the single most useful owner-observable parameter for detecting early pulmonary edema. Owners are instructed to count the respiratory rate when the dog is asleep or resting quietly. A sustained rate above 30 breaths per minute warrants a telephone consultation and often a temporary increase in furosemide. This parameter detects congestion before auscultatory crackles become apparent and allows earlier intervention.

Stage D Therapy: Refractory Heart Failure

Stage D is defined as heart failure that is refractory to standard therapy. These dogs remain congested despite optimized doses of furosemide, pimobendan, an ACE inhibitor, and often spironolactone. The approach at this stage involves intensification of diuresis, addition of adjunctive agents, and frank discussion with the owner about prognosis and quality of life.

Diuretic Intensification Strategies

When furosemide at 2 mg/kg twice daily fails to control congestion, several options exist. The furosemide dose can be increased, but the dose-response curve flattens at higher doses and the risk of azotemia and electrolyte depletion rises. A more effective strategy is to add a thiazide diuretic, such as hydrochlorothiazide, to create sequential nephron blockade. The combination of a loop diuretic and a thiazide produces synergistic diuresis by inhibiting sodium reabsorption at two distinct sites. This combination is potent and can precipitate rapid volume depletion, so it is reserved for hospitalized dogs with close monitoring of renal parameters, electrolytes, and blood pressure.

Torsemide, a longer-acting loop diuretic, is an alternative for dogs that do not respond adequately to furosemide. It has higher oral bioavailability and a longer duration of action, which may provide more consistent diuresis. Conversion from furosemide to torsemide requires careful dose calculation and close monitoring, as the drug is more potent on a milligram basis.

Adjunctive Therapy and Arrhythmia Management

Pimobendan dosing can be increased in Stage D, although the evidence for benefit at higher doses is limited. Some cardiologists use pimobendan three times daily in refractory cases, but this practice is based on clinical experience instead of controlled trials. The drug remains the primary inotropic support, and its withdrawal is associated with acute decompensation.

Supraventricular arrhythmias, particularly atrial fibrillation, are common in dogs with advanced dilated cardiomyopathy and can contribute to hemodynamic compromise. Control of the ventricular response rate is an important therapeutic target, as chronic tachycardia can itself produce or worsen ventricular dysfunction Tachycardia-induced cardiomyopathy: a review of animal models and clinical. Digoxin is the most commonly used agent for rate control in dogs with heart failure because it provides both rate control and mild positive inotropy. Diltiazem is an alternative, but its negative inotropic effect limits its use in dogs with significant systolic dysfunction.

The Role of Antiarrhythmic and Metabolic Therapies

Ventricular arrhythmias are common in dogs with advanced heart failure, particularly those with arrhythmogenic right ventricular cardiomyopathy or myocarditis. Antiarrhythmic therapy is indicated when ventricular arrhythmias are frequent, multiform, or associated with syncope or hemodynamic compromise. Amiodarone and sotalol are the most commonly used agents, but both have significant side effect profiles and require electrocardiographic monitoring.

The failing myocardium is energy-starved, and metabolic modulation has been investigated as an adjunctive strategy. The evidence for clinical benefit from agents such as L-carnitine or taurine supplementation is limited to specific deficiency states, which are rare in dogs. Routine supplementation is not recommended. Similarly, antioxidant therapy has not demonstrated consistent benefit in clinical trials, and the role of reactive oxygen species in cardiovascular disease is complex, with these molecules serving both physiological and pathological functions Reactive oxygen species in cardiovascular disease. Blanket antioxidant strategies are therefore not supported by current evidence.

Monitoring the Treated Patient

The treated heart failure patient requires structured re-evaluation. A recheck examination is scheduled 5 to 7 days after any medication change, then at 1 month, then every 3 to 6 months depending on stability. Each recheck includes body weight, thoracic auscultation, respiratory rate, systolic blood pressure, and renal parameters. An echocardiogram is repeated when there is clinical deterioration, not on a fixed schedule, to reassess chamber dimensions, systolic function, and valvular regurgitation.

The owner's observations are central to monitoring. Weight gain, increased resting respiratory rate, reduced appetite, and lethargy are the earliest indicators of decompensation. Owners should be given clear instructions on when to call the clinic and when to present for emergency care. The distinction between a dog that is stable on medication and one that is slowly decompensating is often made by the owner before it is apparent on physical examination.

Therapeutic adjustment follows a stepwise logic. If the dog is congested, increase diuresis. If the dog is azotemic and dehydrated, reduce diuresis and reassess. If the dog is hypotensive, reduce vasodilator therapy. If the dog is weak and has poor systolic function, consider increasing pimobendan. Each change is made singly, and the dog is reassessed before further adjustment. This disciplined approach avoids the confusion of multiple simultaneous medication changes and allows each intervention to be evaluated on its merits.

Recognized Complications and Early Detection

The most consequential failure mode in treated CHF is the transition from compensated stability to refractory congestion. This transition is often insidious. The earliest detectable change is usually a rise in resting respiratory rate, which precedes auscultable crackles by days. Owners trained to count sleeping respiratory rate provide the most sensitive monitoring signal available in practice. A sustained increase above the patient's individual baseline, typically to greater than 30 to 35 breaths per minute, warrants reevaluation before overt signs return.

Azotemia and electrolyte disturbance constitute the second major complication cluster. Combined therapy with a loop diuretic and an ACE inhibitor suppresses renal perfusion pressure and glomerular filtration simultaneously. The RAAS suppression that provides cardiac benefit also removes compensatory efferent arteriolar constriction, making the kidney vulnerable to prerenal injury when diuresis is aggressive. Serial measurement of creatinine, urea, and potassium at each recheck, with particular attention after any dose escalation, detects this pattern early. The renin-angiotensin-aldosterone system and its suppression reviews the dual role of this cascade in both perpetuating heart failure and mediating diuretic-induced renal compromise.

Hypokalemia is the more common electrolyte disturbance with high-dose furosemide, but hyperkalemia emerges when ACE inhibition and spironolactone are combined, especially in patients with concurrent renal disease. Both extremes predispose to ventricular arrhythmias and worsen myocardial function. Tachycardia-induced cardiomyopathy demonstrates that sustained rapid rates alone can produce reversible ventricular dysfunction, so arrhythmia detection at recheck examinations is not optional.

Common Errors and Corrective Action

The most frequent error in early CHF management is underdosing furosemide at presentation. Clinicians who fear renal decompensation more than pulmonary edema often prescribe a dose that fails to clear congestion, then interpret persistent tachypnea as treatment failure and escalate to second-line agents prematurely. The corrective action is to titrate furosemide against measured endpoints, specifically body weight, respiratory effort, and lung auscultation, over the first 24 to 48 hours, instead of relying on a fixed dose.

A second recurring error is initiating pimobendan and an ACE inhibitor simultaneously with furosemide, then being unable to attribute benefit or adverse effect to any single agent. Sequential introduction, with assessment at each step, permits rational adjustment when problems arise. A related error is continuing furosemide at the acute decompensation dose indefinitely after congestion has cleared. The dry weight concept requires deliberate downward titration to the lowest dose that maintains euvolemia.

A third error is neglecting dietary sodium restriction while optimizing pharmacotherapy. Drug doses escalate to compensate for a high-sodium diet, and the resulting high diuretic requirement amplifies electrolyte and renal risk. Conversely, some clinicians impose such severe sodium restriction that appetite declines and cardiac cachexia accelerates.

Limitations of the Evidence and Divergent Expert Opinion

The ACVIM consensus framework provides structure, but several therapeutic questions remain unresolved. The optimal timing for initiating pimobendan in Stage B2 patients without congestion is one such area. Some cardiologists advocate early initiation based on the drug's positive inotropic and neurohormonal modulating effects, while others defer until Stage C because of cost and the absence of definitive comparative data in asymptomatic dogs. The ACVIM consensus statements acknowledge this uncertainty and leave the decision to clinical judgment.

The role of antioxidant therapy remains contested. Reactive oxygen species are clearly implicated in the progression of myocardial dysfunction, yet blanket antioxidant strategies have not produced consistent clinical benefit in cardiovascular disease. Clinicians should be cautious about recommending nutraceutical antioxidants as primary therapy.

The cytokine hypothesis, supported by evidence that tumor necrosis factor is expressed in failing myocardium and correlates with disease severity, has not translated into effective anticytokine therapy in veterinary patients. Practitioners should not expect anti-inflammatory or immunomodulatory agents to alter CHF progression.

Referral and Escalation Criteria

Referral to a veterinary cardiologist is warranted when a patient requires escalating diuretic doses beyond standard published ranges, when arrhythmias complicate management, when echocardiography is needed to distinguish between conditions with different prognoses, or when the clinician is uncertain whether the diagnosis is truly CHF instead of primary respiratory disease. The MSD Veterinary Manual provides baseline therapeutic frameworks, but specialist input is appropriate when the patient fails to stabilize on a rational three-drug protocol.

Laboratory involvement extends beyond routine biochemistry. Serial NT-proBNP measurement can support therapeutic decisions when clinical signs are ambiguous, though it does not replace imaging. Thyroid testing is indicated in older cats instead of dogs, but in dogs with atrial fibrillation, thyroid evaluation is still appropriate to exclude hyperthyroidism as a contributing tachyarrhythmia.

Regulatory reporting obligations are uncommon in small animal cardiology. They arise primarily when a drug is used in a manner inconsistent with its label, which may trigger adverse event reporting requirements depending on jurisdiction. The AVMA practice resources and the WOAH terrestrial animal health standards describe the professional responsibilities surrounding off-label drug use and adverse event documentation, and clinicians should familiarise themselves with the requirements applicable in their region.

Frequently Asked Questions

How Should I Adjust the Therapeutic Plan When Financial Constraints Limit Diagnostic and Treatment Options?

Prioritize interventions by their impact on survival and quality of life. Pimobendan and furosemide provide the greatest symptomatic and prognostic benefit in Stage C and should be protected in the budget. An ACE inhibitor may be added when funds allow, but do not delay diuretic and inotropic support while awaiting it. For monitoring, thoracic radiographs and body weight are the minimum tools, serial echocardiography is desirable but not essential for routine titration. If renal function cannot be assessed, use conservative furosemide increments and monitor appetite, thirst, and body weight closely. The ACVIM consensus statements provide a framework for prioritizing interventions when resources are limited.

What Monitoring Can I Perform When In-House Laboratory or Imaging Equipment Is Unavailable?

Clinical examination remains the foundation. Track body weight daily or every other day, respiratory rate at rest, heart rate and rhythm, mucous membrane color, capillary refill time, and lung auscultation. Resting respiratory rate is the most reliable owner-observable parameter and should be recorded twice daily. Jugular venous distension and hepatojugular reflux indicate right-sided congestion. If blood pressure measurement is unavailable, use pulse quality, mucous membrane perfusion, and mentation as indirect indicators. When biochemistry is unavailable, monitor appetite, vomiting, and urine output as proxies for renal perfusion. Refer for laboratory assessment when clinical parameters suggest deterioration, as guided by MSD Veterinary Manual recommendations on heart failure monitoring.

How Do I Explain the Rationale for Long-Term Combination Therapy to an Owner Who Expects a Single Cure?

Frame the disease as a chronic, progressive condition managed instead of cured. Explain that the heart's pumping failure triggers compensatory hormone systems that initially help but eventually damage the heart further. Suppression of the renin-angiotensin-aldosterone system is therefore a central goal, as chronic activation promotes fibrosis and remodeling in cardiac and renal tissues renin-angiotensin-aldosterone system suppression. Each drug targets a different mechanism: diuretics remove fluid, pimobendan strengthens contraction, and ACE inhibitors reduce harmful hormone signaling. Use the analogy of managing multiple blood pressure medications in human medicine. Emphasize that stopping one drug can destabilize the others and that dose adjustments are expected over time.

What Are the Key Differences in Managing Heart Failure in Cats Compared With Dogs?

Cats differ substantially in drug tolerance and disease phenotype. Furosemide is used at lower starting doses and titrated more cautiously because cats are prone to azotemia and anorexia. Pimobendan is used in feline hypertrophic cardiomyopathy with congestive failure, but evidence for survival benefit is less robust than in dogs. ACE inhibitors are commonly used in cats with chronic kidney disease, so concurrent renal monitoring is essential. Cats frequently develop arterial thromboembolism, warranting antithrombotic therapy that is rarely needed in dogs. Beta-blockers are used in cats with hypertrophic cardiomyopathy and dynamic outflow obstruction, a context where they are contraindicated or used cautiously in dogs. Consult species-specific references such as the MSD Veterinary Manual for dosing and monitoring differences.

What Records Should I Maintain for a Heart Failure Patient on Long-Term Therapy?

Maintain a flow sheet with date, body weight, resting respiratory rate, heart rate, rhythm, blood pressure, appetite score, and activity level at each visit. Record furosemide dose and any recent adjustments, including the date and reason for change. Document pimobendan, ACE inhibitor, and adjunctive drug doses with formulation and frequency. Note any missed doses or vomiting that could affect drug absorption. Record thoracic radiograph findings, including vertebral heart score and pulmonary vessel size, to track remodeling. Keep a log of renal and electrolyte values with dates. This longitudinal record allows objective assessment of disease progression and supports decisions about escalation, as outlined in AVMA practice resources on medical record keeping.

How Should I Counsel an Owner About the Prognosis and When to Consider Euthanasia?

Discuss prognosis honestly at diagnosis and revisit it at each recheck. Median survival in Stage C is measured in months to a few years, but individual outcomes vary widely. Define specific quality-of-life indicators the owner can track: appetite, willingness to walk, sleeping through the night without respiratory distress, and interest in surroundings. Establish a plan for decompensation, including when to call the clinic and when to present as an emergency. Euthanasia is appropriate when congestion cannot be controlled despite maximal therapy, when the dog experiences frequent respiratory crises, or when the owner cannot maintain the treatment schedule. The ACVIM consensus statements acknowledge that refractory heart failure carries a guarded prognosis and that owner education on endpoints is part of responsible case management.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Reactive oxygen species in cardiovascular disease.. 2011.
• Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies.. 1997.
• The role of tumor necrosis factor in the pathophysiology of heart failure.. 2000.
• Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models.. 2009.
• The renin-angiotensin-aldosterone system and its suppression.. 2019.
• Animal models of human cardiovascular disease, heart failure and hypertrophy.. 1998.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Chronic Kidney Disease: Staging and Therapeutic Plan
• Canine Hypoadrenocorticism: Diagnostic and Therapeutic Monitoring
• Canine and Feline Chronic Diarrhea: Diagnostic and Therapeutic Framework
• Canine Gallbladder Disease: Diagnostic and Therapeutic Approach
• Canine Immune-Mediated Myositis: Diagnostic and Therapeutic Approach

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.